摘要
支气管哮喘(以下简称哮喘)是一种复杂的异质性疾病,常根据严重程度、病因、临床表现进行分类,近年来临床开始关注其表型分类及内型分类法。哮喘内型分为高T2型和低T2型。本文主要综述了不同内型哮喘的生物靶点及靶向药物研究进展,指出高T2型哮喘的生物靶点有免疫球白蛋白E(IgE)、IL-5、IL-4、IL-13、前列腺素D2(PGD2)、IL-33、胸腺基质淋巴细胞生成素(TSLP),其靶向药物包括奥马珠单抗、美泊利单抗、瑞利珠单抗、贝那利珠单抗、度普利尤单抗、替尔泊肽等;低T2型哮喘的生物靶点有IL-8、IL-17、IL-6,其靶向药物仍在研究中。
Bronchial asthma(hereinafter referred to as asthma)is a complex and heterogeneous disease,it is traditionally classified by severity,etiology,and clinical manifestations.Recent clinical shift toward phenotypes and endotypes based classification,particularly the T2-high type and T2-low type.This paper synthesizes current research of biological targets and targeted drugs for different endotypes of asthma,and points out the biological targets of asthma with T2-high type include immunoglobulin E(IgE),IL-5,IL-4,IL-13,prostaglandin D2(PGD2),IL-33,thymic stromal lymphopoietin(TSLP),and their targeted drugs include Omalizumab,Mepolizumab,Reslizumab,Benralizumab,Dupilumab,Tezepelumab and so on.The biological targets of asthma with T2-low type include IL-8,IL-17,IL-6,however,their targeted drugs are still under investigation.
作者
姜玉丽
周凤
齐浩翔
柴鑫华
鲍永霞
JIANG Yuli;ZHOU Feng;QI Haoxiang;CHAI Xinhua;BAO Yongxia(Respiratory Medicine Department,the 2nd Affiliated Hospital of Harbin Medical University,Harbin 150000,China)
出处
《实用心脑肺血管病杂志》
2026年第2期28-33,共6页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
支气管哮喘
生物靶点
生物靶向治疗
综述
Bronchial asthma
Biological targets
Biological targeted therapy
Review
